Santiago Palacios
Palacios Institute of Woman's Health, Antonio Acuña 9, 28009 Madrid, Spain.
ScientificWorldJournal. 2012;2012:846824. doi: 10.1100/2012/846824. Epub 2012 May 2.
Iron deficiency anaemia represents a major public health problem, particularly in infants, young children, pregnant women, and females with heavy menses. Oral iron supplementation is a cheap, safe, and effective means of increasing haemoglobin levels and restoring iron stores to prevent and correct iron deficiency. Many preparations are available, varying widely in dosage, formulation (quick or prolonged release), and chemical state (ferrous or ferric form). The debate over the advantages of ferrous versus ferric formulations is ongoing. In this literature review, the tolerability and efficacy of ferrous versus ferric iron formulations are evaluated. We focused on studies comparing ferrous sulphate preparations with ferric iron polymaltose complex preparations, the two predominant forms of iron used. Current data show that slow-release ferrous sulphate preparations remain the established and standard treatment of iron deficiency, irrespective of the indication, given their good bioavailability, efficacy, and acceptable tolerability demonstrated in several large clinical studies.
缺铁性贫血是一个重大的公共卫生问题,尤其在婴儿、幼儿、孕妇以及月经过多的女性中。口服铁补充剂是一种增加血红蛋白水平和恢复铁储备以预防和纠正缺铁的廉价、安全且有效的方法。有许多制剂可供选择,其剂量、剂型(速释或缓释)和化学状态(亚铁或铁盐形式)差异很大。关于亚铁制剂与铁盐制剂优势的争论仍在继续。在这篇文献综述中,评估了亚铁制剂与铁盐制剂的耐受性和疗效。我们重点关注了比较硫酸亚铁制剂与聚麦芽糖铁复合物制剂的研究,这是两种主要使用的铁制剂形式。目前的数据表明,鉴于其在多项大型临床研究中展现出的良好生物利用度、疗效和可接受的耐受性,缓释硫酸亚铁制剂仍然是缺铁性疾病既定的标准治疗方法,无论其适应症如何。